roche glp-1 drug produces “robust” weight loss in late-stage obesity trial | News Roche, trailing in obesity, showcases

Probiotics promote gut and digestive health, which play a role in overall wellness.*

See how RYBELSUS performed in the PIONEER 3 Trial

Additionally, Members of the European Parliament held their inaugural meeting, signalling political commitment and initiating dialogue on obesity priorities across member states

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and obesity, have shown promise in modulating reward-related brain pathways, suggesting potential benefits in the management of AUD

Discover the complex relationship between GLP-1 medications like Ozempic and pancreatic inflammation, including risk factors, warning signs, and what clinical evidence reveals about this potential side effect.